Claudio Cianferotti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Claudio Cianferotti has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Anna Maria Anastasi
R&D Alfasigma S.p.A., 00071 Pomezia, Roma, Italy
1 shared publicationCaterina Chiapparino
R&D Alfasigma S.p.A., 00071 Pomezia, Roma, Italy
1 shared publication- Elena Cini
Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via A. Moro 2, 53100 Siena, Italy
1 shared publication Elena Ermini
Dipartimento di Biotecnologie, Chimica e Farmacia, Università di Siena, 53100 Siena, Italy
1 shared publication- Elena Petricci
Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via A. Moro, 2, 53100 Siena, Italy
1 shared publication Ferdinando Maria Milazzo
R&D Alfasigma S.p.A., 00071 Pomezia, Roma, Italy
1 shared publication
Latest Publications
- Open Access
- 12 January 2021
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 57 (7) , 867-870
Antibody drug conjugates with hydroxamic acid cargos for histone deacetylase (HDAC) inhibition
Antitumor hydroxamates SAHA and Dacinostat have been linked to cetuximab and trastuzumab through a non-cleavable linker based on the p-mercaptobenzyl alcohol structure. These antibody drug conjugates (ADCs) were able to inhibit HDAC in several tumour cell lines. The cetuximab based ADCs block human lung adenocarcinoma cell proliferation, demonstrating that bioconjugation with antibodies is a suitable approach for targeted therapy based on hydroxamic acid-containing drugs. This work also shows that ADC-based delivery might be used to overcome the classical pharmacokinetic problems of hydroxamic acids.
- 12 January 2021
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 57 (7) , 867-870
Open AccessAntibody drug conjugates with hydroxamic acid cargos for histone deacetylase (HDAC) inhibition
Antitumor hydroxamates SAHA and Dacinostat have been linked to cetuximab and trastuzumab through a non-cleavable linker based on the p-mercaptobenzyl alcohol structure. These antibody drug conjugates (ADCs) were able to inhibit HDAC in several tumour cell lines. The cetuximab based ADCs block human lung adenocarcinoma cell proliferation, demonstrating that bioconjugation with antibodies is a suitable approach for targeted therapy based on hydroxamic acid-containing drugs. This work also shows that ADC-based delivery might be used to overcome the classical pharmacokinetic problems of hydroxamic acids.